A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability (Q46099770)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 March 2009

Language	Label	Description	Also known as
English	A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability	scientific article published on 5 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

author name string

B ten Cate

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

M de Bruyn

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

T Bijma

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

D Samplonius

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

M Schwemmlein

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

G Huls

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

G Fey

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

W Helfrich

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

publication date

5 March 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

23

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1389-1397

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

https://scigraph.springernature.com/pub.10.1038/leu.2009.34

0 references

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

The difficult problem of acute myeloid leukemia in the older adult

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of CD20 expression in relapsed lymphomas after rituximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.34

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46099770&oldid=2092474754"